---

Clinical study to evaluate safety and efficacy of tacrolimus 0.1% eye ointment in treatment of vernal keratoconjunctivitis

---

Original Article

Author Details : Rajni Sethia, R N Kothari, Vivan Desai, Aditya Desai, Anjasi Patel

Volume : 3, Issue : 4, Year : 2017

Article Page : 444-449

Suggest article by email

Get Permission

---

Abstract

Introduction: Vernal keratoconjunctivitis is a seasonally recurring, chronic, allergic bilateral inflammatory disorder of the conjunctiva and cornea caused due to immune mediated hypersensitivity reaction. Tacrolimus is an immunomodulator which induces suppression of T lymphocytes activity and causes reduction of ocular inflammation. Hence, in our present study we aim to evaluate the efficacy of 0.1% tacrolimus eye ointment as first line therapy in the management of Vernal Keratoconjunctivitis.
Materials and Methods: This was a clinical, prospective and interventional study including 100 eyes of 50 patients with VKC which were serially selected. 0.1% tacrolimus eye ointment was instilled twice daily over a period of 12 weeks. On every fortnightly follow up, patients were assessed for 5 symptoms and 4 signs and the severity was graded as 0 (normal), 1+ (mild), 2+ (moderate), or 3+ (severe)in order to evaluate the efficacy of the drug.
Results: There were 50 patients with VKC comprising of 41 males and 09 females. After treatment with Tacrolimus 0.1% eye ointment, there was statistically significant improvement in symptoms of VKC including itching, redness, photosensitivity, foreign body sensation and mucus discharge (P<0.001). Significant improvement in clinical signs of VKC including conjunctival hyperaemia, papillary hypertrophy, giant papillary conjunctivitis and limbal involvement (P<0.001) was seen at the end of the study. No significant adverse effects of tacrolimus were seen in these patients.

Conclusion: Topical 0.1% tacrolimus eye ointment is very effective in the treatment of Vernal Keratoconjunctivitis with minimal long term side effects.

Keywords:  Allergy, Immunosupressant, Inflammatory, Tacrolimus, Vernal keratoconjunctivitis.

How to cite : Sethia R, Kothari R N, Desai V, Desai A, Patel A, Clinical study to evaluate safety and efficacy of tacrolimus 0.1% eye ointment in treatment of vernal keratoconjunctivitis. Indian J Clin Exp Ophthalmol 2017;3(4):444-449

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.